Affiliations: [a] Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA | [b] Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA | [c] Center for RNAi and non-coding RNA, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA | [x] Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, 540 East Canfield Avenue, Detroit, MI, USA | [y] University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA, USA
Correspondence:
[*]
Correspondence author: Anil K. Sood, M.D., Professor, Departments of Gynecologic Oncology and Reproductive Medicine, and Cancer Biology, The University of Texas M. D. Anderson Cancer Center, 1155 Herman Pressler Blvd., Unit 1352, Houston, TX 77030, USA. Tel.: +1 713 745 5266; Fax: +1 713 792 7586; E-mail: [email protected].
Abstract: Epithelial ovarian cancer (EOC) remains the most lethal gynecological malignancy despite several~decades of progress in diagnosis and treatment. Taking advantage of the robust development of discovery and utility of prognostic biomarkers, clinicians and researchers are developing personalized and targeted treatment strategies. This review encompasses recently discovered biomarkers of ovarian cancer, the utility of published prognostic biomarkers for EOC (especially biomarkers related to angiogenesis and key signaling pathways), and their integration into clinical practice.
